TCR Cure specializes in the research, development, and industrialization of tumor immune cell therapy technology, with a primary focus on engineered T cells. By advancing CAR-T, TCR-T, CAR-NK, and TIL immune cell therapy products, they enhance tumor cure rates while reducing mortality, recurrence, and disability associated with tumors. Committed to overcoming cancer, TCR Cure supports patients and doctors in the mission to slow and ultimately cure tumors.
Founded in 2016, TCR Cure operates in the Biotechnology, Health Care, and Pharmaceutical industries. The company recently received a significant $50.00M Series C investment on 01 July 2021. The investors behind this latest funding round were unspecified at this time.
